Literature DB >> 8450194

Immunocytochemical identification of cell types in benign and malignant breast diseases: variations in cell markers accompany the malignant state.

P S Rudland1, S J Leinster, J Winstanley, B Green, M Atkinson, H D Zakhour.   

Abstract

We performed immunocytochemical staining of benign, in situ, and malignant breast disease to identify antigens related to the presence of the major parenchymal cell types of the normal breast. Markers for the epithelial cells, antiserum to epithelial membrane antigen, and three monoclonal antibodies (MAb) to milk-fat globule membranes stained most of the inner cells in benign breast lesions, carcinoma in situ, and invasive carcinomas, but the peripheral cells in benign lesions, as well as in carcinoma in situ, were unstained. MAb to epithelium-specific keratin 18 stained the majority of inner cells in benign breast lesions but comparatively fewer such cells in carcinoma in situ and invasive carcinoma. Markers for the myoepithelial cells, antisera, and MAb to smooth muscle actin and vimentin stained most of the peripheral cells in benign breast lesions and in carcinoma in situ but failed to stain virtually any neoplastic cells in invasive carcinomas. Markers for the basement membrane adjacent to the myoepithelial cells, antiserum, and MAb to laminin and Type IV collagen delineated an intact basement membrane around benign lesions and carcinoma in situ, and fragmented structures in 5-10% of invasive carcinomas; the remaining carcinomas were largely unstained. Markers for both myoepithelial and epithelial cells, keratin MAb PKK2 and LP34, stained most of the inner cells in benign lesions but usually only relatively few malignant cells in carcinoma in situ and invasive carcinomas. Markers for the secretory alveolar cell, MAb to beta- and kappa-casein, stained a few isolated cells in benign lesions, many more inner cells in two such lesions in pregnant females, and none in invasive carcinomas. In conclusion, the myoepithelial cell and, under suitable hormonal conditions, the secretory alveolar cell, are retained in most benign lesions, but they are largely lost in invasive carcinomas.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8450194     DOI: 10.1177/41.4.8450194

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  8 in total

1.  Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas.

Authors:  Socorro María Rodríguez-Pinilla; David Sarrió; Emiliano Honrado; Gema Moreno-Bueno; David Hardisson; Francisco Calero; Javier Benítez; José Palacios
Journal:  J Clin Pathol       Date:  2006-11-14       Impact factor: 3.411

2.  Immunolocalization of alpha-transforming growth factor in the developing rat mammary gland in vivo, rat mammary cells in vitro and in human breast diseases.

Authors:  J McAndrew; P S Rudland; A M Platt-Higgins; J A Smith
Journal:  Histochem J       Date:  1994-04

3.  Profile of estrogen-responsive genes in an estrogen-specific mammary gland outgrowth model.

Authors:  Bonnie J Deroo; Sylvia C Hewitt; Jennifer B Collins; Sherry F Grissom; Katherine J Hamilton; Kenneth S Korach
Journal:  Mol Reprod Dev       Date:  2009-08       Impact factor: 2.609

4.  Statistical association of basal cell keratins with metastasis-inducing proteins in a prognostically unfavorable group of sporadic breast cancers.

Authors:  Suzete de Silva Rudland; Angela Platt-Higgins; John H R Winstanley; Nigel J Jones; Roger Barraclough; Christopher West; Joseph Carroll; Philip S Rudland
Journal:  Am J Pathol       Date:  2011-06-14       Impact factor: 4.307

5.  A list of candidate cancer biomarkers for targeted proteomics.

Authors:  Malu Polanski; N Leigh Anderson
Journal:  Biomark Insights       Date:  2007-02-07

6.  Comparative expression of fibroblast growth factor mRNAs in benign and malignant breast disease.

Authors:  S Y Anandappa; J H Winstanley; S Leinster; B Green; P S Rudland; R Barraclough
Journal:  Br J Cancer       Date:  1994-04       Impact factor: 7.640

7.  Models of breast cancer: quo vadis, animal modeling?

Authors:  Kay-Uwe Wagner
Journal:  Breast Cancer Res       Date:  2003-10-31       Impact factor: 6.466

8.  Increased risk of malignant progression in benign proliferating breast lesions defined by expression of heat shock protein 27.

Authors:  P A O'Neill; A M Shaaban; C R West; A Dodson; C Jarvis; P Moore; M P A Davies; D R Sibson; C S Foster
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.